Genentech CFO Lou Lavigne to retire
Thursday, 11 November, 2004
Genentech has announced that its chief financial officer, Lou Lavigne, will retire next March and will be replaced by David Ebersman, currently senior vice president of product operations.
Ebersman joined Genentech in 1994 and was named senior director of product development in 1998, vice president of product development in 1999 and senior vice president of product operations in 2001.
He became a member of Genentech's executive committee in March 2004.
Before joining Genentech, Ebersman was a research analyst covering biotechnology at Oppenheimer & Company, which is now CIBC World Markets. Ebersman will be replaced by Pat Yang, currently vice president of South San Francisco Manufacturing and Engineering.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
